Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
401actual
Sites
68
Countries
Belgium, Hungary, India +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-12-21 | actual | When the study began enrolling |
| Primary completion | 2021-01-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-27 | estimated | The whole study's end, after follow-up |
| First posted | 2018-12-14 | actual | When this record first appeared on the registry |
| Results posted | 2022-12-12 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-05-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-small Cell Lung Cancer NSCLC
Interventions
- Drug: Durvalumab — also filed as MEDI4736 (Durvalumab)
- Drug: Placebo for Olaparib — also filed as Placebo
- Drug: Olaparib — also filed as AZD2281 (Olaparib)
- Drug: Nab-paclitaxel+carboplatin
- Drug: Gemcitabine+carboplatin
- Drug: Pemetrexed+carboplatin
- Drug: Gemcitabine+cisplatin
- Drug: Pemetrexed+cisplatin
Primary outcome
what the primary-completion date above is the date OFProgression-free Survival
measured From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2020-07-14 · 7.9 MB · Prot_000.pdf
Statistical Analysis Planposted 2020-11-09 · 2.7 MB · SAP_001.pdf
Publications
- PMID 37390980 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed